Compare Quest Diagnostics Inc (DGX) vs iShares 1 3 Year Treasury Bond ETF (SHY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs iShares 1 3 Year Treasury Bond ETF — how do they compare? Quest Diagnostics Inc trades at $205.26 (market cap $22.80B), while iShares 1 3 Year Treasury Bond ETF trades at $81.99. The key difference: Quest Diagnostics Inc pays a 1.67% dividend while iShares 1 3 Year Treasury Bond ETF pays none, and Quest Diagnostics Inc is trading nearer its 52-week high, iShares 1 3 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| DGX | SHY | |
|---|---|---|
Market Cap | $22.80B | — |
Sector | Health | Fixed Income |
52-Week High | $216.02 | $83.18 |
52-Week Low | $166.42 | $81.79 |
Enterprise Value | $28.82B | — |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
SHY, a US Treasury bond ETF, trades at $81.79, down 0.11% with a bearish technical signal from moving averages. The fund maintains consistent dividend distributions of $0.24 per share scheduled through mid-2026. Current market sentiment reflects significant investor interest in cash and Treasury ETFs as bond yields rise, with nearly $100 billion flowing into cash ETFs according to recent reports.
The outlook for SHY remains tied to Federal Reserve policy decisions amid inflation concerns. While the ETF provides stable income through Treasury exposure, rising rate expectations could pressure short-term bond prices. Investors seeking yield may find competition from higher-yielding alternatives as Treasury yields approach 4% levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About iShares 1 3 Year Treasury Bond ETF
SHY provides exposure to U.S. Treasury bonds with remaining maturities between one and three years. It is a low-risk, highly liquid ETF designed for capital preservation and short-term income, featuring 2026 top holdings across various Treasury Notes.
Read more on SHY →
